Under construction – not a live service
Sign in
Taking people in CanadaNo phase

Testing an AI chatbot that gives health information for several conditions

Tests the MARVIN AI chatbot for information on HIV, breast cancer and emergencies in children.

Plain-language title generated from the registry record
Registry title: The MARVIN Chatbots to Provide Information for Different Health Conditions

Key facts

Where
Montreal, CanadaSee the 2 sites

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 14 or older who speak English and/or French and can use a smartphone, tablet or computer with internet. It tests chatbots that give health information.

Age
14 years or older
Sex
All sexes can join.

Main reasons for not taking part

  • Cannot understand the study requirements or give informed consent
  • No smartphone, tablet or computer, or no internet connection
  • Not fluent in English and/or French
  • Any reason, in the investigator's opinion, that makes joining a chatbot study inappropriate (for example, cognitive deficit)

Read by machine on 9 November 2026.

Where in Canada

  • Centre Hospitalier de l'Universite de Montreal (CHUM)Montreal, CanadaTaking people
  • McGill University Health Centre (MUHC)Montreal, CanadaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
McGill University Health Centre/Research Institute of the McGill University Health Centre
Trial code
NCT05789901
Record updated
6 March 2024
Original description
This research is a continuation of a usability study with the MARVIN chatbot. The investigators aim to adapt the MARVIN chatbot to open it to other health domains (e.g. breast cancer) and populations (e.g. pharmacists). Therefore, this protocol constitutes a master research protocol that will englobe different research projects with individual chatbots. The investigators adopt an adaptive platform trial design, which will allow flexibility in handling multiple interventions adapted to different populations while retaining the characteristics of a platform trial design allowing early withdrawal of ineffective trial arms based on interim data (implementation outcomes) and introduction of new trial arms.Read full original descriptionShow less

A Master Research Protocol to Adapt and Evaluate an Artificial Intelligence Based Conversational Agent to Provide Information for Different Health Conditions: the MARVIN Chatbots

This research is a continuation of a usability study with the MARVIN chatbot. The investigators aim to adapt the MARVIN chatbot to open it to other health domains (e.g. breast cancer) and populations (e.g. pharmacists). Therefore, this protocol constitutes a master research protocol that will englobe different research projects with individual chatbots. The investigators adopt an adaptive platform trial design, which will allow flexibility in handling multiple interventions adapted to different populations while retaining the characteristics of a platform trial design allowing early withdrawal of ineffective trial arms based on interim data (implementation outcomes) and introduction of new trial arms.

Inclusion: being 14 years or older; being fluent in English and/or French; being able to understand the requirements of study participation and provide informed consent during the duration of the study; having access to a smartphone, tablet, or computer at home/at workplace; having access to an internet connection at home or data plan on their device; accept to use a Facebook Messenger-based Chatbot; accept to use or create a personal Facebook account; accept Facebook's privacy and data security policies.

Exclusion: not meeting the inclusion criteria; any reason, in the opinion of the investigator, which would make the candidate inappropriate for participation in an investigative study involving a chatbot (e.g., cognitive deficit).

ClinicalTrials.gov NCT05789901